Forkhead class O transcription factor 3a activation and Sirtuin1 overexpression in the hypertrophied myocardium of the diabetic Goto-Kakizaki rat

Journal of Hypertension

Volumn 26, Issue 2, 2008, Pages 334-344

  Vahtola, Erik ^a   Louhelainen, Marjut ^a   Merasto, Saara ^a   Martonen, Essi ^a   Penttinen, Satu ^a   Aahos, Ilkka ^a   Kytö, Ville ^b   Virtanen, Ismo ^a   Mervaala, Eero ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Apoptosis; FOXO3a; Goto Kakizaki rat; Hypertrophy; p53; Sirt1; Type 2 diabetes

Indexed keywords

ALDOSTERONE; BETAINE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CASPASE 3; NORADRENALIN; PROTEIN BAX; SIRTUIN 1; TRANSCRIPTION FACTOR FKHRL1;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; GENE OVEREXPRESSION; HEART FUNCTION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FOLDING; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 38149097912     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282f293c8     Document Type: Article

References (56)

1. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332:73-78.
2. Bell DS. Heart failure: the frequent, forgotten, and often fatal complication of diabetes. Diabetes Care 2003; 26:2433-2441.
3. Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 2003; 42:206-212.
4. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, et al. Apoptosis in the failing human heart. N Engl J Med 1997; 336:1131-1141.
5. Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 1998; 40:239-247.
6. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25:543-567.
7. Foo RS, Mani K, Kitsis RN. Death begets failure in the heart. J Clin Invest 2005; 115:565-571.
8. von Harsdorf R, Li PF, Dietz R. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation 1999; 99:2934-2941.
9. Giordano FJ. Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest 2005; 115:500-508.
10. Morris BJ. A forkhead in the road to longevity: the molecular basis of lifespan becomes clearer. J Hypertens 2005; 23:1285-1309.
11. Guarente L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev 2000; 14:1021-1026.
12. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107:137-148.
13. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A 2003; 100:10794-10799.
14. McBurney MW, Yang X, Jardine K, Hixon M, Boekelheide K, Webb JR, et al. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol Cell Biol 2003; 23:38-54.
15. Guarente L. Sirtuins as potential targets for metabolic syndrome. Nature 2006; 14:868-874.
16. Haigis M, Guarente L. Mammalian sirtuins - emerging roles in physiology, aging and calorie restriction. Genes Dev 2006; 20:2913-2921.
17. Shore D. The Sir2 protein family: a novel deacetylase for gene silencing and more. Proc Natl Acad Sci U S A 2000; 97:14030-14032.
18. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403:795-800.
19. Ahmet I, Wan R, Mattson MP, Lakatta EG, Talan M. Cardioprotection by intermittent fasting in rats. Circulation 2005; 112:3115-3121.
20. Alcendor RR, Kirshenbaum LA, Imai S, Vatner SF, Sadoshima J. Silent information regulator 2alpha, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes. Circ Res 2004; 95:971-980.
21. SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 2001; 107:149-159.
22. Furukawa-Hibi Y, Kobayashi Y, Chen C, Motoyama N. FOXO transcription factors in cell-cycle regulation and the response to oxidative stress. Antioxid Redox Signal 2005; 7:752-760.
23. Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in FOXO's road. Sci STKE 2003; 172:1-11.
24. Van Der Heide LP, Hoekman MF, Smidt MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004; 380:297-309.
25. Giannakou ME, Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 2004; 14:408-412.
26. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116:551-563.
27. Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1α. J Biol Chem 2005; 280:16456-16460.
28. Goto Y, Kakizaki M, Masaki N. Production of spontaneous diabetic rats by repetition of selective breeding. Tohoku J Exp Med 1976; 119:85-90.
29. Cheng ZJ, Vaskonen T, Tikkanen I, Nurminen K, Ruskoaho H, Vapaatalo H, et al. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 2001; 37:433-439.
30. Janssen U, Phillips AO, Floege J. Rodent models of nephropathy associated with type II diabetes. J Nephrol 1999; 12:159-172.
31. El-Omar MM, Yang ZK, Phillips AO, Shah AM. Cardiac dysfunction in the Goto-Kakizaki rat. A model of type 2 diabetes. Basic Res Cardiol 2004; 99:133-141.
32. Desrois M, Sidell RJ, Gauguier D, Davey CL, Radda GK, Clarke K. Gender differences in hypertrophy, insulin resistance and ischemic injury in the aging type 2 diabetic rat heart. J Mol Cell Cardiol 2004; 37:547-558.
33. Finckenberg P, Inkinen K, Ahonen J, Merasto S, Louhelainen M, Vapaatalo H, et al. Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol 2003; 163:355-366.
34. Helkamaa T, Finckenberg P, Louhelainen M, Merasto S, Rauhala P, Lapatto R, et al. Entacapone protects from angiotensin II-induced inflammation and renal injury. J Hypertens 2003; 21:2353-2363.
35. Wasmeier GH, Melnychenko I, Voigt JU, Zimmermann WH, Eschenhagen T, Schineis N, et al. Reproducibility of transthoracic echocardiography in small animals using clinical equipment. Coron Artery Dis 2007; 18:283-291.
36. Galli J, Fakhrai-Rad H, Kamel A, Marcus C, Norgren S, Luthman H. Pathophysiological and genetic characterization of the major diabetes locus in GK rats. Diabetes 1999; 48:2463-2470.
37. Janssen U, Riley SG, Vassiliadou A, Floege J, Phillips AO. Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. Kidney Int 2003; 63:2162-2170.
38. Cheng ZJ, Gronholm T, Louhelainen M, Finckenberg P, Merasto S, Tikkanen I, Mervaala E. Vascular and renal effects of vasopeptidase inhibition and angiotensin-converting enzyme blockade in spontaneously diabetic Goto-Kakizaki rats. J Hypertens 2005; 23:1757-1770.
39. Dorn GW 2nd, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115:527-537.
40. 2+ release in cardiomyocytes. Nat Cell Biol 2001; 3:867-873.
41. Saad MJ, Velloso LA, Carvalho CR. Angiotensin II induces tyrosine phosphorylation of insulin receptor substrate 1 and its association with phosphatidylinositol 3-kinase in rat heart. Biochem J 1995; 310 (Pt 3):741-744.
42. Franke TF, Kaplan DR, Cantley LC. PI3K: downstream AKTion blocks apoptosis. Cell 1997; 88:435-437.
43. Muslin AJ. Role of raf proteins in cardiac hypertrophy and cardiomyocyte survival. Trends Cardiovasc Med 2005; 15:225-229.
44. Desrois M, Sidell RJ, Gauguier D, King LM, Radda GK, Clarke K. Initial steps of insulin signaling and glucose transport are defective in the type 2 diabetic rat heart. Cardiovasc Res 2004; 61:288-296.
45. Song XM, Kawano Y, Krook A, Ryder JW, Efendic S, Roth RA, et al. Muscle fiber type-specific defects in insulin signal transduction to glucose transport in diabetic GK rats. Diabetes 1999; 48:664-670.
46. Steiler TL, Galuska D, Leng Y, Chibalin AV, Gilbert M, Zierath JR. Effect of hyperglycemia on signal transduction in skeletal muscle from diabetic Goto-Kakizaki rats. Endocrinology 2003; 144:5259-5267.
47. Kobayashi Y, Furukawa-Hibi Y, Chen C, Horio Y, Isobe K, Ikeda K, Motoyama N. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med 2005; 16:237-243.
48. Skurk C, Izumiya Y, Maatz H, Razeghi P, Shiojima I, Sandri M, et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J Biol Chem 2005; 280:20814-20823.
49. Matsui T, Tao J, del Monte F, Lee KH, Li L, Picard M, et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001; 104:330-335.
50. Jünger MA, Rintelen F, Stocker H, Wasserman JD, Vegh M, Radimerski T, et al. The Drosophila forkhead transcription factor FOXO mediates the reduction in cell number associated with reduced insulin signaling. J Biol 2003; 2:20.
51. Crow MT, Mani K, Nam Y-J. The mitochondrial death pathway and cardiac myocyte apoptosis. Circ Res 2004; 95:957-970.
52. Friedman JS, Lowe SW. Control of apoptosis by p53. Oncogene 2003; 22:9030-9040.
53. Waf1/Cip1. Mol Cell Biol 2006; 26:2782-2790.
54. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303:2011-2015.
55. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305:390-392.
56. Backs J, Olson EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006; 98:15-24.